The NADPH-dependent reduction of chromium (VI), a known carcinogen, by hepatic microsomes was very similar for all five humans examined, with an apparent K m for chromate of 1.04-1.68 µM, and a V max of 10.4-10.7 nmol/ min/mg protein. Inhibitor studies indicate no role for cytochrome P450s, but a prominent role for flavoproteins, which could include P450 reductase, flavin-containing mono-oxygenase and cytochrome b 5 . Relative to anaerobic conditions, Cr(VI) reduction was inhibited only 26-37% by room air, which indicates that human microsomal Cr(VI) reduction could still proceed at significant rates, even in tissues with high O 2 tensions. Studies with lung microsomes from one human exhibited V max and K m values that were two-thirds lower and 2.8-fold greater, respectively, than those of hepatic microsomes from the same individual; other Cr(VI)-reducing parameters were similar for lung and liver. Various forms of exogenous iron, when present at 0.76-6.3 µM, markedly enhanced both liver and lung microsomal rates and V max of Cr(VI) reduction, but did not significantly alter the other Cr(VI)-reducing parameters (K m , effects of O 2 and inhibitors). These iron levels were 3.1-to 26-fold lower than the initial Cr(VI) concentration, which suggests that iron is serving a catalytic role. The ratio of human microsomal Cr(VI) reduction rates under aerobic versus anaerobic conditions remained fairly constant, regardless of iron concentration. Small increases in intracellular iron could therefore lead to large increases in the rate and extent of microsomal Cr(VI) reduction. Individuals that are simultaneously exposed to Cr(VI) and to agents that increase intracellular iron could therefore be at potentially greater risk for Cr(VI) toxicity and carcinogenicity.
Introduction
Exposure to chromium (Cr) compounds is associated with a wide array of toxic effects, including increased incidence of certain cancers (1) (2) (3) (4) (5) , serious damage to internal organs (e.g. lungs, liver, kidneys) (2, 4, 6) , pulmonary fibrosis and chronic bronchitis (7) , skin ulcers and allergic dermatitis (7) , and impairment of primary immune responses (8) . The inhalation of Cr-containing fumes, dusts and particles is primarily associated with respiratory tract damage (5, 9, 10) , whereas exposure to forms that are internalized is associated with toxicity to other organs including liver and kidneys (11, 12) . Epidemiologic studies on the occupational exposure to Cr compounds provide the primary source of information on Cr toxicity and carcinogenicity in humans (5, 10, (13) (14) (15) .
The solubility and membrane permeability of various Cr compounds likely play key roles in Cr toxicity/carcinogenicity. Cr(III) compounds are generally quite insoluble and, as such, do not easily cross cell membranes (16) , in contrast, Cr(VI) compounds, many of which are soluble, readily cross the skin (7) and are readily transported across cell membranes (17) via an anion carrier (18) . Cr compounds are also mutagenic (19) , and the bulk of in vitro studies have implicated exposure to Cr(VI) as the predisposing factor to Cr-induced genotoxicity (20) (21) (22) (23) . Incubation of human lymphocytes with Cr(VI) results in an increased number of DNA strand breaks (24) , and an increase in DNA-protein crosslinks in human lymphocytes is observed in persons who live in Cr-contaminated areas or who are occupationally exposed to Cr (14, 15) . However, Cr(VI) is probably not itself the toxic species. Rather, the reduction of Cr(VI) to Cr(III), and the resulting formation of reactive intermediates Cr(V) and/or Cr(IV), seems to be a key component in the cytotoxicity and genotoxicity of Cr(VI) compounds (23, 25, 26) . Reactive oxygen species, which can be generated during the reduction of Cr(VI), may contribute to the toxicity and carcinogenicity of Cr compounds (25, (27) (28) (29) (30) .
The molecular mechanisms of the genotoxic and cytotoxic effects of Cr(VI) are, at best, only partially understood, and most studies have utilized rodents or purified reducing agents to elucidate potential reductive processes and their implications. In rodents, several cellular components are capable of reducing Cr(VI) at physiological pH, including glutathione (25, 31) , ascorbate (31, 32) , cysteine (25, 31) , H 2 O 2 (25) , NADPH (25, 33) and cytochromes P450 (34) (35) (36) . Due to the high K m for chromate and extreme oxygen sensitivity, a significant physiological role for rodent microsomal enzymes is questionable, and it is assumed that ascorbate is likely to be among the prominent non-enzymatic reductants of Cr(VI) in rodents (25, 32) .
However, there is very little information on the mechanisms of Cr(VI) reduction in humans and, in a preliminary report using hepatic tissue from primarily one human, certain key differences in microsomal Cr(VI) reduction were noted between rodents and humans (37) . Specifically, the human system was much less oxygen-sensitive, had a much greater affinity for chromate, and was not mediated by cytochromes P450, but rather by unidentified flavoproteins (37) .
Since the levels and nature of the reductants can significantly influence the levels and types of reactive intermediates generated, it is questionable if the rodent studies can and should be extrapolated to humans as a means to thoroughly understand Cr toxicity. Therefore, to better understand Cr(VI) toxicity and the potential for Cr-induced carcinogenesis in humans, the preliminary studies on the role of human microsomal enzymes in the reductive transformation of Cr(VI) were extended to include more individuals and to examine other key issues. Results that include five hepatic samples and one lung sample support our initial findings and demonstrate little interindividual variability with respect to Cr(VI) reduction. Iron, at micromolar levels, was able to significantly increase the rate of microsomal Cr(VI) reduction. Humans who are simultaneously exposed to Cr(VI) and to compounds that increase intracellular iron could, therefore, be at much greater risk for the toxic and carcinogenic effects of Cr(VI). In all cases, the organs were removed from brain-dead organ transplant donors by the Organ Transplant Unit within~30 min after death. The tissue was immediately iced, cut into small pieces, flash-frozen in liquid nitrogen, and stored at -80°C as previously described (37) .
Materials and methods

Chemicals
Liver tissue from five humans (patients B, C, F, N and O) and lung tissue from one (patient O) was used. A partial characterization of the P450 isozyme contents of the hepatic microsomes from four of these subjects has been published (38, 39) . The pertinent patient data are as follows (38) : human B, male, age 50, no known drug history, heavy smoker; human C, male, age 22, ethanol detected; human F, female, age 50, alcoholic, diabetic, heavy smoker; human N, male, age 21, ethanol detected (0.087%), unknown smoking history; human O, male, age 49, unknown history. For hepatic microsomes, total cytochrome P450 contents were 0.16, 0.33, 0.24, 0.30 and 0.26 nmol P450/ mg protein, and P450 reductase activities were 89, 73, 109, 87 and 110 nmol cytochrome c reduced/min/mg protein for patients B, C, F, N and O, respectively. For human lung O microsomes, total cytochrome P450 content was below detectable limits and P450 reductase activity was 37 nmol cytochrome c reduced/min/mg protein.
Microsomal fractions were prepared from human tissue using a conventional differential centrifugation procedure as previously described (37) .
Cr(VI) reduction assay
Experiments to assess Cr(VI) reductase activity were conducted as previously described (37) , using an NADPH-regenerating system (3 mM MgCl 2 , 1 mM NADP, 7 mM G6P and 0.4 U G6P dehydrogenase/ml) at 37°C. Microsomes were pre-incubated for 5 min prior to the addition of Na 2 CrO 4 to a final concentration of 19.6 µM. Net enzymatic rates were obtained by subtracting the slow rates [probably the result of a slow chemical reduction by NADPH (40) ] that were observed in the presence of pre-boiled microsomes [which were previously shown to lack enzymatic activity (37) ]. The reduction of Cr(VI) was stopped by the addition of 125 µl 2 M Na 2 CO 3 (per 2.5 ml reaction volume) (40) . The concentration of the remaining Cr(VI) was measured colorimetrically by 1,5-diphenyl-carbazide (DPC) in acid solution (pH 2) (41) after removal of interfering reducing material by a charcoal/ aluminium oxide mixture (42) . Cr(VI) concentrations were determined from a standard curve with Na 2 CrO 4 as the standard by measuring absorbance at 540 nm against a blank in which Na 2 CrO 4 was omitted. In some experiments, the NADPH-dependence of the reduction of Cr(VI) was assessed by removing individual components of the NADPH-generating system.
Experiments to examine the kinetics of microsomal Cr(VI) reduction were performed in an analogous manner, except that different concentrations of Na 2 CrO 4 were used and all reactions were stopped after 3 min.
Experiments under anaerobic conditions (4-5% H 2 /balance N 2 ) were conducted in a Coy anaerobic chamber (Coy Laboratory Products, Inc., Grass Lake, MI). All buffers, etc., were pre-incubated in the anaerobic chamber for at least 1 h before use. Cr(VI) reduction rates under these conditions were found to be indistinguishable from those in which the vials were made 1030 anaerobic by flushing with O 2 -free N 2 . For those experiments conducted under aerobic conditions, open-top vials were incubated in a shaking water-bath (100 r.p.m.) during all steps; for these vials, the reagents were not preincubated under anaerobic conditions.
Effects of potential inhibitors on Cr(VI) reduction
The effect of CO on Cr(VI) reduction was examined as follows: microsomal preparations that had been rendered anaerobic were gassed with 100% CO on ice for 2 min and then pre-incubated for 5 min at 37°C prior to addition of Na 2 CrO 4 in the Cr(VI) reduction assay. Controls were gassed under identical conditions with O 2 -free N 2 , which was generated by passing 100% high purity dry grade N 2 through an Oxi-Clear cartridge (Labclear, Oakland, CA).
For the other inhibitor experiments, the inhibitor was added at the same time as the NADPH-generating system and was therefore exposed to the microsomes during the 5-min pre-incubation period. The following stock solutions were made just before use: n-octylamine (0.3 M), aminopyrine (0.3 M) and piperonyl butoxide (6 mM) were prepared in DMSO; TlCl 3 (13.1 mM) and metyrapone (6.25 mM) were prepared in 10 mM HEPES, pH 7.5. Final inhibitor concentrations were as indicated in the results. For each inhibitor, Cr(VI) reduction rates were compared with those in the presence of the inhibitor solvent only.
Pretreatment of microsomes with 0.2 mM 2-bromo-4Ј-nitroacetophenone (BNAP), which inhibits microsomal NADPH:cytochrome c reductase, was done as described (43) , and compared against controls in which BNAP was omitted.
Determination of the iron content of solutions
To determine the iron content of G6Ps and other solutions used in the chromium reduction assay, solutions were mixed with freshly prepared sodium hydrosulfite (final concentration, 10 mM) to reduce all iron to Fe(II). Different aliquots (50-500 µl) of these solutions were then processed through the ferrozine assay (44, 45) to determine the concentration of Fe(II). Calculations were made to account for volume differences to determine the amount of Fe contributed by each solution. No iron was detected in the 10 mM sodium hydrosulfite solution.
Reduction of ferric citrate by microsomes
Ferric reductase activity was assayed under anaerobic conditions by monitoring the production of Fe(II) over time as adapted from Myers and Myers (46) . All solutions were pre-incubated in the anaerobic chamber for at least 1 h before use. The assays were performed at 37°C in temperature-controlled stirred anaerobic cuvettes using an Aminco anaerobic cell accessory (SLM Instruments, Urbana, IL); the assay mix (3.0 ml total volume) consisted of: 28 mM potassium phosphate buffer (pH 7.5), 0.4 mM ferrozine, 0.12 mM ferric citrate and 0.18-0.26 mg of microsomal protein. The anaerobic cuvettes were set up in an anaerobic chamber in a 37°C heating block, and sealed before removal from the chamber to maintain anaerobic conditions. The assay was started by the addition of 60 µl 50 mM anaerobic NADPH to the sample cuvette (using the sealed plunger device of the anaerobic cell accessory); the reference cuvette received 60 µl anaerobic water at the same time. Activity was followed by an increase in absorbance over 3 min at 562 nm. Rates of Fe(III) reduction in the absence of microsomes, which were minimal, were subtracted from microsomal rates to obtain the net values due to microsomal activity. Using the extinction coefficient for the ferrozine-Fe(II) complex of 28/mM/cm (47), changes in absorbance were converted to nmol of ferrozineFe(II) complex formed (equivalent to nmol Fe(III) reduced) per min at 37°C.
Miscellaneous procedures
Microsomal protein concentrations were determined by the Lowry method (48) modified as described to remove potential interference from detergents (49) , with bovine serum albumin as the standard. Total cytochrome P450 content was determined from reduced-CO minus the reduced spectra as described (50) using an Aminco DW-2000 spectrophotometer (SLM-Aminco Instruments, Urbana, IL); the difference in absorbances at 450 and 490 nm was used to calculate the molar concentration of P450, using an extinction coefficient of 91/mM/cm (51). NADPH:cytochrome P450 reductase activity was measured at 37°C as cytochrome c reduction (52); the change in absorbance at 550 nm was followed over time in a 1-ml volume containing 0.1 µmol NADPH, 34 nmol cytochrome c 'type III', 50 mM potassium phosphate (pH 7.7), 1 mM cyanide and 0.1 to 0.5 mg microsomal protein (ε ϭ 29.5/mM/cm for reduced cytochrome c).
The rate of formation of NADPH in the presence of the NADPHregenerating system (3 mM MgCl 2 , 1 mM NADP, 7 mM G6P and 0.4 U G6P dehydrogenase/ml) was measured at 37°C; the change in absorbance at 340 nm (ε ϭ 6.1/mM/cm for NADPH) was followed over time in a 2.5-ml reaction volume containing 150 mM KCl/25 mM HEPES, pH 7.35. 
Results
Cr(VI) reduction properties of human hepatic microsomes
We have completed a thorough analysis of various parameters of Cr(VI) reduction catalyzed by hepatic microsomes from five individuals, and the results follow the trends seen in our preliminary report (37) . The findings, which are summarized in Table I , show no major interindividual differences, which suggests that the responsible components are present at similar levels in different individuals. In all cases, Cr(VI) reduction was enzymatic and NADPH-dependent, and rates were proportional to the amount of microsomes added. Of special note, and in marked contrast to rodent studies, are the very low K m for Cr(VI) (1.04 to 1.68 µM), and the lack of effect of any of the cytochrome P450 inhibitors (Table I) . These results are not likely to be a function of unusual or low P450 levels in these individuals, since published data (38, 39) indicate that they represent a broad range of levels of various P450 isoforms. Atmospheric levels of O 2 inhibited only a minority of the Cr(VI) reduction activity ( Table I ), suggesting that these enzymes can function at significant rates even in tissues with high O 2 tensions. TlCl 3 , an inhibitor of flavoproteins including P450 reductase (53), almost completely abolished Cr(VI) reduction (Table I) . Its ability to completely inhibit NADPHdependent cytochrome c reductase (P450 reductase) (37) suggests a potential role for this enzyme in Cr(VI) reduction. The inhibitory effect of BNAP (Table I) , which inhibited Ͼ90% of the P450 reductase activity (not shown), further implicates a role for P450 reductase (43) ; while BNAP can also inhibit certain cytochrome P450s (54), the lack of effect of other P450 inhibitors (Table I) suggests that the effects of BNAP are caused by its ability to inhibit P450 reductase. Partial inhibition by n-octylamine (55,56) suggests a possible role for flavin-containing mono-oxygenase (FMO) ( Table I) . While n-octylamine acts as a type II inhibitor of certain P450s, the lack of inhibition by all other P450 inhibitors suggests that its effects are FMO-linked rather than P450-linked (57) . None of these inhibitor effects are because of significant inhibition of the NADPH-generating system in these assays (37) . 
Stimulation of Cr(VI) reduction by cytochrome b 5
While the inhibitor studies suggest a significant role for P450 reductase in microsomal Cr(VI) reduction, the lack of effect of cytochrome P450 inhibitors suggests that P450 reductase is not acting in concert with cytochromes P450. Rather, P450 reductase is either directly mediating Cr(VI) reduction and/or is acting as part of a multi-component system with other as yet unidentified microsomal component(s). One such possible component is cytochrome b 5 , which can accept electrons from P450 reductase (58) . This possibility is supported by the observation that when we added purified human recombinant cytochrome b 5 to human N microsomes, the rate of Cr(VI) reduction more than doubled (Table II) . Since these experiments were conducted in the presence of NADPH, it is unlikely that cytochrome b 5 was acting in cooperation with cytochrome b 5 reductase, as the latter is an NADH-dependent microsomal flavoenzyme (59) .
Role of iron in human microsomal Cr(VI) reduction
After completing the above characterizations of human microsomal Cr(VI) reduction using monopotassium glucose-6-phosphate (G6P) in the NADPH-generating system, supplier problems forced us to switch to other G6Ps. Unexpectedly, this resulted in significant changes in the Cr(VI) reduction rates, with each G6P supporting a different rate of Cr(VI) reduction by human hepatic microsomes (Figure 1 ). Since the manufacturers had only very limited data on these different forms of G6P, extensive trial-and-error investigation revealed the following about the various G6Ps: (i) on the basis of UV spectra, there were no detectable contaminants in any of the G6Ps; (ii) G6P stock solutions did not display pH differences that could explain the different rates of Cr(VI) reduction; (iii) none of the G6Ps, when used as part of the NADPH-generating mix, catalyzed significant levels of Cr(VI) reduction in the absence of microsomes; and (iv) all of the G6Ps supported essentially identical rates of NADPH generation, which were Ͼ100-fold the observed rates of microsomal Cr(VI) reduction. However, additional analyses revealed that there were significant differences in the iron content of the various G6Ps: those with higher iron content were associated with higher rates of microsomal Cr(VI) reduction (Figure 2) , and while the G6P contributed a large part of the total iron in the Cr reduction assays, the rates of Cr(VI) reduction correlated most strongly with the total iron present and not just that contributed by G6P (Figure 2 ). There was some lot-to-lot variation in the iron content of these various G6Ps, especially with monopotassium G6P. Regardless of the G6P lot, the microsomal Cr reduction rate varied in proportion to the total iron content of the assay (not shown). reduction by human hepatic microsomes. The salts and suppliers of G6P were as follows: K (monopotassium G6P, Sigma); Na (monosodium G6P, Sigma); K2(S) (dipotassium G6P; Sigma); K2(RO) (dipotassium G6P, Research Organics). Results shown represent the mean Ϯ SD, n ϭ 3. The values are relative to those using monopotassium G6P whose mean was arbitrarily set at 1.00.
Fig. 2.
Correlation between the relative Cr(VI) reduction rate by human hepatic microsomes and the iron content of the G6P salt or the total reaction mix. The salts and suppliers of G6P were as follows: K (monopotassium G6P, Sigma); Na (monosodium G6P, Sigma); K2(S) (dipotassium G6P; Sigma); K2(RO) (dipotassium G6P, Research Organics).
Results shown represent the mean of three determinations.
While the exact chemical nature of the iron contamination in the various G6Ps is not known, the iron is probably complexed with the phosphate group. The addition of other forms of exogenous iron (e.g. FeCl 3 , FeSO 4 ) to the microsomal Cr(VI) reduction experiments similarly enhanced the rates of Cr(VI) reduction (Figures 3 and 4) . Additions of FeCl 3 , which resulted in total iron amounts of 1.93 to 16.1 nmol Fe, caused marked increases in Cr(VI) reduction rates, while additional increases in total Fe (16.1 to 44.1 nmol) had little to no effect Final total reaction volume was 2.55 ml, and the initial amount of Cr(VI) was 50 nmol. Results shown represent the mean Ϯ SD, n ϭ 3; for points lacking apparent error bars, the bars were smaller than the points as shown. Final total reaction volume was 2.55 ml, and the initial amount of Cr(VI) was 50 nmol. Results shown represent the mean Ϯ SD, n ϭ 3; for points lacking apparent error bars, the bars were smaller than the points as shown.
on further increasing Cr(VI) reduction rates ( Figure 3) . The trend was similar for additions of FeSO 4 : a change in total iron from 2.13 to 9.96 nmol markedly increased the rate of microsomal Cr(VI) reduction, and a further increase to 18.5 nmol Fe caused an incremental but less pronounced increase in Cr(VI) reduction rate (Figure 4 ). Further additions of FeSO 4 to increase total Fe from 18.5 to 50.8 nmol, did not result in further significant increases in Cr(VI) reduction (Figure 4 ). The maximal rates of Cr(VI) reduction are approximately one-third greater for FeSO 4 addition (Figure 4 ) relative to FeCl 3 addition (Figure 3 ). Other studies have noted that Figure 3 ) were similar to those that were obtained using monopotassium-G6P in our initial experiments; the high iron content of experiments that included monopotassium-G6P (Figure 2 ) are consistent with these higher Cr(VI) reduction rates.
Since the initial characterizations of human microsomal Cr(VI) reduction (Table I) were done prior to the discovery of the effect of iron, Cr(VI) reduction parameters were reassessed using G6Ps with significantly different iron levels (Table III) . These comparisons demonstrated that the concentration of iron markedly influenced the rate and V max of Cr(VI) reduction (Table III; Figures 3 and 4) . Other Cr(VI)-reducing parameters (e.g. K m , inhibition by n-octylamine) were only influenced to a small extent by large differences in the concentration of iron (Table III) .
Since Fe(II) can be readily oxidized by O 2 (64) , additional experiments were done to determine the effects of O 2 on Cr(VI) reduction at various iron concentrations. The ratio of human microsomal Cr(VI) reduction rates under aerobic versus anaerobic conditions remained fairly constant, regardless of iron concentration ( Figure 5 ). Even though iron varied from 1.93 to 16.1 nmol, aerobic Cr(VI) reduction rates for human O were 63-71% of the anaerobic rates ( Figure 5 ). For human N, a similar ratio range was observed.
The absolute rates of Cr(VI) and Fe(III) reduction were compared for hepatic microsomes from three humans, and in all cases, the rate of Fe(III) reduction was marginally greater than the rate of Cr(VI) reduction (Table IV) . Theoretically, the rate of reduction of Fe(III) is therefore sufficient to support the rate of Cr(VI) reduction.
Role of iron in Cr(VI) reduction by human lung microsomes
Since the lungs are also a potential target organ for chromium toxicity, the effect of iron on the rate of Cr(VI) reduction by lung microsomes from patient O was determined. Lung microsomal Cr(VI) reduction rates of 0.81 Ϯ 0.03 and 0.16 Ϯ 0.02 nmol/min per mg protein were observed for experiments in which the total iron content was 4.86 and 1.54 nmol, respectively. While this relative effect of iron is similar to what we had previously observed using liver microsomes from patient O, the Cr(VI) reduction rates catalyzed by lung microsomes are lower than those obtained using hepatic microsomes. This is consistent with the lower V max for Cr(VI) reduction observed with lung microsomes (3.6 Ϯ 0.7 nmol/min per mg), which is approximately onethird of the hepatic V max in this patient. The apparent K m for Cr(VI) for lung microsomes is 4.6 µM, which is 2.8-fold greater than that of liver microsomes in the same patient. Similar to the liver, various cytochrome P450 inhibitors did not affect Cr(VI) reduction by lung microsomes. As for liver, lung microsomal Cr(VI) reduction was stopped by heatdenaturing the microsomes or by excluding NADPH (not shown). Also similar to the liver, TlCl 3 markedly inhibited lung microsomal Cr(VI) reduction, which suggests a role for flavoproteins.
Discussion
The results reported here support and extend our preliminary findings (37) , and demonstrate that the rates and basic properties of human microsomal Cr(VI) reduction are very similar in different individuals (Table I) . As in rodents (35) , human microsomal Cr(VI) reduction is NADPH-dependent. The V max in human hepatic microsomes (10.4-10.7 nmol/min/mg protein) is somewhat greater than that reported for control rats (6.4 Ϯ 0.1 nmol/min/mg protein) (35) . In a preliminary report (37) , the V max reported for human N was 5.03 nmol/min per mg protein. However, this was obtained using a different lot of G6P for which the iron content was not determined. Since it is now apparent that the level of iron can markedly influence the V max of Cr(VI) reduction (Table III) , it is likely that this earlier lot of G6P had a lower Fe level, which would account for the lower V max . However, with respect to other key properties, the microsomal Cr(VI)-reducing system in humans is very distinct from that in rats. The apparent K m for chromate of the human system (1-1.7 µM) is orders of magnitude lower than that reported for rat liver microsomes (1.6 mM) (34) . This implies that humans could be more susceptible to Cr(VI)-reductionlinked cellular damage, as the microsomal Cr(VI)-reducing enzymes would likely be active at Cr(VI) concentrations that are reasonable for expected occupational or environmental exposure.
A relative insensitivity to O 2 is also a general property of the human microsomal Cr(VI)-reducing system, with room air (21% O 2 ) causing only a 26-37% inhibition relative to anaerobic conditions (Table I ). This is in marked contrast to microsomal Cr(VI) reduction in rats, which is markedly inhibited by 0.1% O 2 , and completely inhibited by 1% O 2 (35, 40) . This implies that human microsomal Cr(VI) reduction would still proceed at significant rates even in tissues with high O 2 tensions. The limited O 2 -sensitivity of the human system could imply the existence of more than one Cr(VI)-reducing enzyme, at least one of which is O 2 -insensitive and at least one which is fully O 2 -sensitive. Alternatively, there could be a single Cr(VI)-reducing system that is only partially inhibited by O 2 . At this point, the inhibitor data suggest the existence of more than one Cr(VI)-reducing component, i.e. inhibitors of P450 reductase and FMO are both able to partially block microsomal Cr(VI) reduction (Table I) .
In marked contrast to rodents, in which cytochrome P450(s) can mediate Cr(VI) reduction (35, 36, 40) , none of the human microsomes displayed any sensitivity to various cytochrome P450 inhibitors. However, marked inhibition by TlCl 3 suggests a prominent role for flavoproteins in humans; the effects of TlCl 3 could be caused by its potential action as a flavoprotein antagonist and/or as an inhibitor of the active sulfhydryl groups of P450 reductase (53) . Partial inhibition of Cr(VI) reduction by n-octylamine suggests a potential role for FMO. FMOs have broad substrate specificity for organic nitrogen and sulfur compounds, as well as some inorganic ions including HS -, I -, IO -and SCN -(65); interaction with CrO 4 2-is therefore not out of the realm of possibility. While the oxidative potential of FMOs is well-known (66), their role as mediators of reductive processes remains largely unexplored. While there are several FMO isoforms, FMO3 (formerly FMO II) appears to be predominant in human liver (67, 68) .
Prominent inhibition by BNAP suggests a possible role for NADPH:cytochrome P450 reductase. The relative O 2 tolerance of the human Cr(VI)-reducing system is also consistent with a potential role for P450 reductase, as this enzyme can reduce nitrofurantoin under aerobic conditions (69) . While purified rat P450 reductase can, when present at high levels, reduce Cr(VI), this activity is very O 2 -sensitive (36) . If human P450 reductase is involved in microsomal Cr(VI) reduction, it must be much less O 2 -sensitive than the rat enzyme.
Since other microsomal enzymes, including cytochromes P450 and b 5 , are dependent upon electron flow from P450 reductase, the effects of P450 reductase inhibitors (e.g. TlCl 3 , BNAP) do not necessarily implicate P450 reductase as a direct Cr(VI)-reducing enzyme. However, the lack of effect of several P450 inhibitors eliminates an essential or prominent role for cytochrome P450s. In contrast, significant stimulation of microsomal NADPH-dependent Cr(VI) reduction by cytochrome b 5 (Table II) suggests a potential role for this microsomal component. In our preliminary studies with human O, we observed that Cr(VI) reduction rates catalyzed by lung microsomes were approximately one-third of those for liver. This is consistent with the fact that the levels of P450 reductase and cytochrome b 5 in human lung are~20-25% of those in human liver (70) , and with our data suggest that P450 reductase and cytochrome b 5 are involved in human microsomal Cr(VI) reduction. Since the P450 reductase and cytochrome b 5 expressed in various tissues are apparently identical [i.e. there are not different isoforms in different tissues (71, 72) ], it seems likely that these enzymes could also contribute to Cr(VI) reduction in non-hepatic tissues, so long as they are present at adequate levels. When taking into account that, in the lung, P450 reductase is primarily localized in bronchial and bronchiolar epithelial cells (71) , it seems likely that the concentration of P450 reductase in these bronchial epithelial cells is as great or greater than that in hepatic cells and could therefore make a significant contribution to Cr(VI) reduction. While these epithelial cells comprise a minority of the cells in the lung, they are major sites of exposure from inhaled Cr(VI) and of pulmonary tumors including those related to Cr exposure. However, the contribution of microsomal enzymes, relative to other enzymatic and non-enzymatic cellular components to total cellular Cr(VI) reduction, remains to be determined.
The apparent K m for Cr(VI) for lung microsomes (4.6 µM) is well within the realm of occupational exposure and is consistent with a potentially prominent role for microsomal enzymes in the lung. It must be understood that there are many different cell types in the lung, so studies with lung microsomes only provide a conglomerate of the Cr(VI) reduction process in various cell types. As noted above, the differential expression of suspect Cr(VI)-reducing enzymes among various lung cell types suggests that different components may be responsible for Cr(VI) reduction in different cell types or that certain cell types could display significantly different rates of Cr(VI) reduction. Nonetheless, the general properties of microsomal Cr(VI) reduction in human lung do not appear to be markedly different from those in liver from the same patient, and are consistent with a potentially significant role for microsomal enzymes, at least in some lung cell types. Additional studies with lungs from other humans will have to be done to determine if, like for liver, there is little interindividual variability in Cr(VI)-reducing properties.
Since redox transformations of both iron and chromium can lead to oxidative damage (73) , the ability of low concentrations of iron to markedly stimulate Cr(VI) reduction in both lung and liver human microsomes could have significant consequences. Specifically, we observed that human microsomal Cr(VI) reduction rates are markedly stimulated by increases in iron from 0.76-6.3 µM, which is 3.1-to 26-fold lower than the initial Cr(VI) concentration in our assays. This level of iron is consistent with levels reported in other studies for which iron was shown to contribute to cell-damaging processes. For example, following myocardial ischemia, iron levels in the coronary flow fraction increase from 0.36 µM to 2.86 µM (74). In another study, while increases in iron concentration from 0 to 50 µM are associated with increases in lipid peroxidative damage, the majority of the effect on lipid peroxidation occurs at iron levels below 10 µM (75).
Rat microsomes, cytochrome b 5 , and P450 reductase can all reduce Fe(III)-EDTA (61, 64) , as can porcine P450 reductase and cytochrome b 5 (64) . Hence, the data that suggest a role for these enzymes in human Cr(VI) reduction are consistent with their potential role in iron reduction, and the apparent link between iron and Cr(VI) reduction in humans.
The characterization of the levels and exact nature of low molecular weight or 'bioavailable' iron within cells remains obscure, possibly because the chemistry of such pools is diverse. Hence, exact levels of 'bioavailable' iron have not yet been established for any cell type. While it is generally accepted that the majority of intracellular iron is sequestered in ferritin, it is clear that there are intracellular pools of iron, distinct from ferritin, that are directly involved in mediating oxidative cell injury: these pools represent from 2-15% of total cellular iron, depending on various conditions (76) . For example, this pool is increased~3-fold in animals treated with either phenobarbital or 3-methylcholanthrene (76) . While this pool of iron may be enhanced by oxidative stress, such stress is not required for its existence (76) . The regulation of certain mRNAs by intracellular chelatable iron levels is also consistent with the existence of pools of low molecular weight or bioavailable iron (77, 78) .
Since Cr(VI) reduction was markedly stimulated by Fe levels that were 3.1-to 26-fold lower than the initial Cr(VI) concentration, it seems likely that Fe is serving a catalytic role. Since Fe(II) can directly reduce Cr(VI) (62, 63) , one possible scenario is that a small amount of Fe is repeatedly redox-cycled, resulting in the reduction of a much larger amount of Cr(VI). This has potentially significant toxicologic consequences, as the rate and extent of formation of reactive Cr intermediates could be greatly amplified by relatively small increases in intracellular iron. Since the oxidation of Fe(II) to Fe(III) by Cr(VI) represents a one-electron process, it seems likely that Cr(V) would be the resulting immediate product provided that Fe was limiting, as is the case for our human microsomal experiments. The formation of Cr(V) can lead directly to the generation of reactive oxygen species, which are probably responsible for at least some of the damage associated with Cr(VI) exposure, e.g. DNA strand breaks, DNA-protein crosslinks and lipid peroxidation (25, 26, 30, 79) . Cr(V) can also catalyze the formation of lipid hydroperoxide radicals from previously existing lipid peroxides (80) .
The formation of reactive oxygen species from reactive Cr intermediates requires the presence of O 2 and O 2 metabolites. This is consistent with our findings that human microsomal Cr(VI) reduction still proceeds at significant rates under room air (Table I) . Theoretically, one might expect that O 2 should markedly inhibit both Cr(VI) and iron reduction, as is the case in rats (35, 40, 60) . While O 2 could theoretically inhibit any role for iron by rapidly oxidizing Fe(II) to Fe(III), it is known that, below pH 10, the rate of Fe(II) oxidation by Cr(VI) is greater than the rate of Fe(II) oxidation by O 2 (63) . This is consistent with our findings in humans that any inhibition of Cr(VI) reduction by O 2 is independent of the iron level ( Figure 5 ). Hence, in humans, O 2 should have same effect regardless of iron level, i.e. iron can significantly stimulate 1035 Cr(VI) reduction rates under both anoxic and fully oxic conditions.
The accumulation of Cr(III) over time may also contribute to the genotoxicity of Cr (81) . Because Cr(III) is kinetically inert to ligand substitution, Cr-DNA adducts (82) are very stable and persistent (83) . However, only certain types of Cr(III) complexes are potentially mutagenic (84) . Furthermore, the formation of these Cr-DNA adducts is probably a result of the reductant process itself, as higher levels of Cr-DNA adducts are observed under conditions that favor the formation of Cr(V), whereas fewer adducts are seen under conditions favoring Cr(III) and Cr(IV) formation (85) . So while Cr(III) is presumed to be the ultimate oxidation state that is bound to DNA, it seems that reactive Cr intermediates, e.g. Cr(V), are more likely to form the initial Cr-DNA complexes (85, 86) . Once bound, Cr(III) may subsequently be formed either by further reactions between Cr(V) and DNA or other potential reductants (85) .
At this point, it is unclear whether human microsomal Cr(VI) reduction is totally linked to iron, or whether some portion of the activity is not dependent on iron. Since microsomal rates of Fe(III) reduction are marginally higher than Cr(VI) reduction rates (Table IV) , it is theoretically possible that Fe(III) reduction could account for all Cr(VI) reduction. However, it is impossible to completely exclude iron from these experiments, as microsomes contain iron in various forms, including that contained in heme groups, iron-sulfur centers, etc. However, if one extrapolates the lines in Figures  3-5 back to zero iron, all of the lines imply some Cr(VI)-reducing activity in the absence of iron. This extrapolated 'iron-independent' activity comprises 13-30% of the maximal Cr(VI)-reducing activity under high iron for those experiments in which FeCl 3 served as the source of exogenous iron, and 8-15% of the maximal Cr(VI)-reducing activity for those experiments in which FeSO 4 served as the source of exogenous iron. Future experiments with purified microsomal enzymes will be required to discern if certain enzymes operate independently of iron while others are iron-dependent, or if certain enzymes generally possess some degree of iron-independent Cr(VI) reduction but operate more efficiently in the presence of iron.
In the presence of rat microsomes or active NADPH:P450 reductase, any one of several compounds (paraquat, benzyl viologen, diquat, triphenyltetrazolium, nitrofurantoin, doxorubicin, daunomycin, diaziquone, anthraquinone 2-sulfonate) can mediate significant release of iron from ferritin (60, 78) , with rates of 1.2-6.3 µM/min/U P450 reductase (78) . The ability of these xenobiotics to increase intracellular iron levels could therefore have significant toxicologic consequences for simultaneous exposure to Cr(VI) and one or more of these compounds. In addition, both nitric oxide and superoxide can also mediate iron release from ferritin (78) , so conditions that lead to increases in these free radical species could also potentially enhance Cr(VI) reduction rates and hence chromium-related cytotoxicity. In summary, the levels of iron for which we observe significant effects on Cr(VI) reduction are generally in line with levels at which iron is known to mediate other effects, and are within the range of what could be expected within a cell.
Mikalsen et al. (62) have shown that certain iron chelates can increase the rate of NADPH-linked Cr(VI) reduction by rat microsomes. They proposed that the rat P450 reductase reduces Fe(III)-EDTA to Fe(II)-EDTA, with Fe(II) serving as the ultimate reducer of Cr(VI) (62) . This was supported by the findings that rat P450 reductase cannot reduce Cr(VI) if Fe(III)-EDTA is absent, and that substituting ADP-Fe(III) (which is a poor acceptor of electrons from the rat P450 reductase) for Fe(III)-EDTA resulted in much lower rates of Cr(VI) reduction (62) . These studies provide a possible mechanism by which Fe may be stimulating the Cr(VI) reduction rates by human microsomes. However, the extrapolation of these rodent studies to humans is not necessarily direct, as there are several discrepancies or differences from the human studies reported here. First, the rat studies utilized Fe(III)-EDTA, whereas FeCl 3 , FeSO 4 , or an iron contaminant in G6P served as the source of iron for the human studies reported here. We also noted that human microsomes could efficiently reduce Fe(III) citrate (Table IV) . Second, the rat studies required very high levels of iron chelates (50-150 µM), which were 1.7-to 5-fold higher than the level of Cr(VI) (62) . In contrast, in our human studies, Cr(VI) reduction was stimulated by Fe in the range of 0.76-6.3 µM which is 3.1-to 26-fold lower than initial Cr(VI) levels. Hence, human Cr(VI) reduction rates are stimulated by iron at levels that are 8-to 197-fold lower than those used in the rat studies. While the exact mechanism of Cr(VI) and/or Fe(III) reduction in human microsomes is not yet clear, the effects of iron on the rate of Cr(VI) reduction occur at much lower iron concentrations in humans versus rats. Iron is thus much more likely to play a significant role in Cr(VI) reduction in humans because these lower iron concentrations are likely to be more readily achieved.
In summary, our findings implicate a NADPH-linked, relatively oxygen-insensitive enzymatic system for the reduction of Cr(VI) in human hepatic microsomes. Results using microsomes from different individuals were very similar, and preliminary results with human lung were, in most respects, similar to those of liver. Flavoprotein(s) seem to play a major role while cytochromes P450 play little or no role. In comparison with the rat, the human microsomal Cr(VI) reduction system is also much less sensitive to O 2 and displays a much higher affinity for Cr(VI). Various forms of exogenous iron, at micromolar levels, markedly enhanced both liver and lung microsomal rates and V max of Cr(VI) reduction, but did not significantly alter the other Cr(VI)-reducing parameters. These iron levels were much lower than the initial Cr(VI) concentration, which suggests that iron is serving a catalytic role. The ratio of human microsomal Cr(VI) reduction rates under aerobic versus anaerobic conditions remained fairly constant, regardless of iron concentration. Small increases in intracellular iron could therefore lead to large increases in the rate and extent of microsomal Cr(VI) reduction. Individuals that are simultaneously exposed to Cr(VI) and to agents that increase intracellular iron could therefore be at potentially greater risk for Cr(VI) toxicity and carcinogenicity. While the evidence at this point suggests possible roles for P450 reductase, cytochrome b 5 , and/or FMOs in human microsomal Cr(VI) and/or iron reduction, additional experiments will be necessary to further investigate the exact role of these enzymes.
